A meta-analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiotherapy
- PMID: 38396380
- PMCID: PMC10891363
- DOI: 10.1002/cam4.7023
A meta-analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiotherapy
Abstract
Background: This study aimed to compare the outcomes of proton beam therapy (PBT) and carbon ion radiotherapy (CIRT) by a systematic review and meta-analysis of the existing clinical evidence.
Methods: A systematic literature search was performed to identify studies comparing the clinical outcomes of PBT and CIRT. The included studies were required to report oncological outcomes (local control [LC], progression-free survival [PFS], or overall survival [OS]) or adverse events.
Results: Eighteen articles comprising 1857 patients (947 treated with PBT and 910 treated with CIRT) were included in the analysis. The pooled analysis conducted for the overall population yielded average hazard ratios of 0.690 (95% confidence interval (CI), 0.493-0.967, p = 0.031) for LC, 0.952 (95% CI, 0.604-1.500, p = 0.590) for PFS, and 1.183 (0.872-1.607, p = 0.281) for OS with reference to CIRT. The subgroup analyses included patients treated in the head and neck, areas other than the head and neck, and patients with chordomas and chondrosarcomas. These analyses revealed no significant differences in most outcomes, except for LC in the subgroup of patients treated in areas other than the head and neck. Adverse event rates were comparable in both groups, with an odds ratio (OR) of 1.097 (95% CI, 0.744-1.616, p = 0.641). Meta-regression analysis for possible heterogeneity did not demonstrate a significant association between treatment outcomes and the ratio of biologically effective doses between modalities.
Conclusion: This study highlighted the comparability of PBT and CIRT in terms of oncological outcomes and adverse events.
Keywords: carbon ion radiotherapy; meta-analysis; oncologic outcome; particle beam radiotherapy; proton beam therapy; toxicity.
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures


Similar articles
-
Proton beam and carbon ion radiotherapy in skull base chordoma: a systematic review, meta-analysis and meta-regression with trial sequential analysis.Neurosurg Rev. 2024 Dec 7;47(1):893. doi: 10.1007/s10143-024-03117-1. Neurosurg Rev. 2024. PMID: 39644344 Free PMC article.
-
Comparison of Oncologic Outcomes and Treatment-Related Toxicity of Carbon Ion Radiotherapy and En Bloc Resection for Sacral Chordoma.JAMA Netw Open. 2022 Jan 4;5(1):e2141927. doi: 10.1001/jamanetworkopen.2021.41927. JAMA Netw Open. 2022. PMID: 34994795 Free PMC article.
-
Hadrontherapy for cancer. An overview of HTA reports and ongoing studies.Recenti Prog Med. 2019 Dec;110(12):566-586. doi: 10.1701/3278.32516. Recenti Prog Med. 2019. PMID: 31909760 Review. English.
-
Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy.Neuro Oncol. 2020 Sep 29;22(9):1348-1358. doi: 10.1093/neuonc/noaa067. Neuro Oncol. 2020. PMID: 32193546 Free PMC article.
-
Effectiveness and Safety of Carbon Ion Radiotherapy in Solid Tumors: A Systematic Review and Meta-Analysis.Yonsei Med J. 2024 Jun;65(6):332-340. doi: 10.3349/ymj.2023.0439. Yonsei Med J. 2024. PMID: 38804027 Free PMC article.
Cited by
-
Comparisons of clinical characteristics, treatments, and outcomes among different pathological subtypes of chondrosarcoma in the spine.J Neurooncol. 2024 Dec;170(3):641-653. doi: 10.1007/s11060-024-04823-y. Epub 2024 Sep 14. J Neurooncol. 2024. PMID: 39276177
-
Cost-Effectiveness of Carbon Ion Radiotherapy in Oncology: A Systematic Review.Cureus. 2025 May 13;17(5):e84008. doi: 10.7759/cureus.84008. eCollection 2025 May. Cureus. 2025. PMID: 40364864 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources